All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage IIIb stage IIIc stage IV (metastatic) stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/adv melanoma (mML), nivolumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 066, 2015 0.42 [0.25; 0.72]
CheckMate 066 DUPLICATE, 2015 0.36 [0.24; 0.55]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.54 [1.25; 1.89]
CheckMate 238, 2017 0.87 [0.66; 1.14]
0.68 [0.40 ; 1.15 ] CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017 5 93% 3,003 low serious deaths (OS) (extension)detailed results CheckMate 066, 2015 0.46 [0.36; 0.59]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.20 [0.97; 1.49]
0.71 [0.41 ; 1.20 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 3 95% 1,679 low not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
0.73 [0.56 ; 0.96 ] CheckMate 238, 2017 1 0% 735 NA not evaluable PFS (extension)detailed results CheckMate 066, 2015 0.42 [0.33; 0.53]
CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.27 [1.03; 1.55]
0.66 [0.34 ; 1.26 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 3 97% 1,679 low not evaluable progression or deaths (PFS)detailed results CheckMate 066, 2015 0.43 [0.34; 0.55]
CheckMate 066 DUPLICATE, 2015 0.43 [0.34; 0.55]
CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.35 [1.09; 1.67]
0.62 [0.34 ; 1.10 ] CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 4 96% 2,097 low not evaluable RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
0.71 [0.59 ; 0.85 ] CheckMate 238, 2017 1 0% 906 NA not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
IMMUNED (N vs P ; all population), 2020 0.56 [0.33; 0.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2.50 [1.26; 4.97]
0.92 [0.45 ; 1.89 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 86% 1,132 low not evaluable DOR (extension)detailed results CheckMate 066, 2015 3.45 [1.46; 8.18]
3.45 [1.46 ; 8.18 ] CheckMate 066, 2015 1 0% 120 NA not evaluable objective responses (ORR)detailed results CheckMate 066, 2015 4.06 [2.52; 6.54]
CheckMate 066 DUPLICATE, 2015 4.06 [2.52; 6.54]
CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.57 [0.42; 0.78]
2.35 [0.77 ; 7.20 ] CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 4 96% 2,097 low not evaluable objective responses (ORR) (extension)detailed results CheckMate 066, 2015 4.50 [2.79; 7.25]
CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.17 [0.12; 0.24]
1.38 [0.16 ; 11.98 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 3 99% 1,679 low not evaluable AE (any grade)detailed results CheckMate 066, 2015 0.78 [0.34; 1.76]
CheckMate 238, 2017 0.49 [0.20; 1.23]
0.63 [0.35 ; 1.17 ] CheckMate 066, 2015, CheckMate 238, 2017 2 0% 1,316 low not evaluable AE (grade 3-4)detailed results CheckMate 066, 2015 0.84 [0.56; 1.25]
CheckMate 238, 2017 0.28 [0.21; 0.37]
0.48 [0.16 ; 1.41 ] CheckMate 066, 2015, CheckMate 238, 2017 2 95% 1,316 low not evaluable AE leading to death (grade 5)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.97 [0.10 ; 9.38 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 628 low not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 066, 2015 0.55 [0.28; 1.10]
CheckMate 238, 2017 0.15 [0.10; 0.21]
IMMUNED (N vs P ; all population), 2020 3.57 [0.71; 18.07]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.23]
0.34 [0.11 ; 1.04 ] CheckMate 066, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 89% 1,533 low not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 066, 2015 0.61 [0.29; 1.28]
CheckMate 238, 2017 0.11 [0.07; 0.18]
IMMUNED (N vs P ; all population), 2020 4.90 [0.55; 43.46]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.25]
0.31 [0.09 ; 1.14 ] CheckMate 066, 2015, CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 88% 1,534 low not evaluable SAE (any grade)detailed results CheckMate 066, 2015 0.73 [0.49; 1.10]
IMMUNED (N vs P ; all population), 2020 1.27 [0.56; 2.87]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.27 [0.12; 0.59]
0.64 [0.30 ; 1.34 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 74% 628 low not evaluable SAE (grade 3-4)detailed results CheckMate 066, 2015 0.74 [0.47; 1.17]
IMMUNED (N vs P ; all population), 2020 2.51 [0.94; 6.74]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.29 [0.13; 0.63]
0.78 [0.29 ; 2.12 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 82% 629 low not evaluable STRAE (any grade)detailed results CheckMate 066, 2015 1.06 [0.54; 2.07]
IMMUNED (N vs P ; all population), 2020 6.13 [1.29; 29.17]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.08; 0.41]
0.94 [0.17 ; 5.12 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 89% 628 low not evaluable STRAE (grade 3-4)detailed results CheckMate 066, 2015 0.99 [0.44; 2.27]
IMMUNED (N vs P ; all population), 2020 19.34 [1.09; 342.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.21 [0.09; 0.52]
0.97 [0.17 ; 5.43 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 84% 629 low not evaluable TRAE (any grade)detailed results CheckMate 066, 2015 0.93 [0.60; 1.46]
CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.28 [0.15; 0.53]
CheckMate 238, 2017 0.25 [0.15; 0.43]
IMMUNED (N vs P ; all population), 2020 4.29 [1.74; 10.57]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.20 [0.04; 0.96]
0.65 [0.30 ; 1.39 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 89% 2,784 low not evaluable TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.62 [0.35; 1.08]
CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.21 [0.15; 0.29]
CheckMate 238, 2017 0.20 [0.14; 0.27]
IMMUNED (N vs P ; all population), 2020 5.85 [1.58; 21.65]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.15 [0.07; 0.34]
0.44 [0.22 ; 0.86 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 92% 2,784 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.66 [0.13 ; 3.47 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 2,372 low serious TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.21 [0.14; 0.31]
CheckMate 238, 2017 0.12 [0.08; 0.17]
IMMUNED (N vs P ; all population), 2020 7.29 [0.86; 61.51]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.23]
0.30 [0.12 ; 0.74 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 92% 2,372 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.20 [0.12; 0.32]
CheckMate 238, 2017 0.09 [0.05; 0.15]
IMMUNED (N vs P ; all population), 2020 9.90 [0.53; 186.01]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.25]
0.23 [0.09 ; 0.56 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 87% 2,373 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
CheckMate 238, 2017 0.50 [0.02; 14.96]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.56 [0.13 ; 2.41 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low serious Acute kidney injury TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.64 [0.05 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.07; 1.64]
CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.56 [0.21 ; 1.47 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 2,373 low not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.96 [0.10 ; 9.32 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 629 low not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.73 [0.08 ; 6.29 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 629 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.04; 5.52]
CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4.04 [0.18; 91.59]
1.15 [0.35 ; 3.79 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.50 [0.02; 14.88]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.06; 16.06]
CheckMate 238, 2017 0.25 [0.03; 2.24]
0.45 [0.12 ; 1.66 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017 4 0% 2,566 low not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
2.98 [0.27 ; 32.69 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
0.91 [0.02 ; 46.72 ] IMMUNED (N vs P ; all population), 2020 1 0% 107 NA not evaluable Chills TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.11 [0.03; 0.36]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.16 [0.01; 3.19]
0.12 [0.06 ; 0.28 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 0% 1,468 low not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
1.00 [0.02 ; 50.40 ] CheckMate 066, 2015 1 0% 411 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 4.02 [0.18; 89.49]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
2.01 [0.42 ; 9.75 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 1,879 low serious Decreased appetite TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.12 [0.01; 2.35]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.46 [0.09 ; 2.24 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 1,879 low serious Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.94 [0.27 ; 13.89 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.18; 22.23]
CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.29 [0.13; 0.62]
CheckMate 238, 2017 0.15 [0.07; 0.34]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.06; 16.10]
0.36 [0.18 ; 0.69 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 39% 2,784 low not evaluable Dizziness TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.17 ; 5.66 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 1,879 low not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Dyspepsia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.03; 3.20]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.67 [0.14 ; 3.21 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 0% 1,468 low not evaluable Ear and labyrinth disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.02; 1.61]
0.39 [0.05 ; 3.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 20% 218 low not evaluable Eye disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.64 [0.05 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.25 [0.01; 5.51]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.22 [0.06; 0.79]
CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.43 [0.20 ; 0.96 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low not evaluable Gastritis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.40 [0.03 ; 4.62 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.10 [0.05; 0.20]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.11 [0.01; 0.89]
0.13 [0.04 ; 0.40 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 25% 1,123 low not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.40 [0.03 ; 4.62 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.25 [0.01; 5.54]
CheckMate 238, 2017 0.14 [0.02; 1.15]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.34 [0.10 ; 1.23 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low serious Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.10 [0.01; 1.81]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.30 [0.06; 1.57]
0.42 [0.11 ; 1.55 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 5% 1,468 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.15 [0.07; 0.32]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.13 [0.03; 0.63]
0.22 [0.06 ; 0.77 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 50% 1,123 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 238, 2017 2.01 [0.07; 59.97]
1.49 [0.11 ; 19.39 ] CheckMate 066, 2015, CheckMate 238, 2017 2 0% 1,316 low not evaluable Hypertension TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.17 [0.01; 3.31]
CheckMate 238, 2017 1.00 [0.06; 16.07]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.16 [0.01; 3.19]
0.54 [0.14 ; 2.03 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.20 [0.02; 1.70]
CheckMate 238, 2017 0.18 [0.04; 0.81]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
0.27 [0.10 ; 0.73 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 2,373 low serious Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.70 [0.17 ; 2.79 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low serious Increase AST TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.06; 16.02]
CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.15 [0.04; 0.51]
CheckMate 238, 2017 0.10 [0.02; 0.44]
IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.33 [0.08; 1.33]
0.40 [0.14 ; 1.16 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 54% 2,784 low serious Increased ALT TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.18; 22.23]
CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.14 [0.05; 0.40]
CheckMate 238, 2017 0.18 [0.07; 0.48]
IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.05; 0.68]
0.36 [0.15 ; 0.89 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 57% 2,784 low serious Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.38 [0.20; 0.73]
IMMUNED (N vs P ; all population), 2020 0.91 [0.17; 4.70]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.33 [0.08; 1.33]
0.60 [0.30 ; 1.18 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 45% 1,468 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.96 [0.10 ; 9.32 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 629 low not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.12 [0.01; 2.33]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.36 [0.05 ; 2.73 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 629 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.07; 1.64]
CheckMate 238, 2017 0.05 [0.00; 0.95]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.48 [0.17 ; 1.36 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.06; 16.10]
1.26 [0.14 ; 10.99 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6.17 [0.30; 126.14]
5.94 [0.70 ; 50.19 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.06; 16.06]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.46 [0.33 ; 6.44 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 1,879 low not evaluable Myositis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.07 [0.00; 1.24]
CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.44 [0.11 ; 1.80 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low serious Nervous system disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2.00 [0.18; 22.72]
2.53 [0.37 ; 17.24 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.05 [0.00; 0.92]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.23 [0.03 ; 1.71 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 629 low not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Pancytopenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.16 [0.01; 3.29]
0.16 [0.01 ; 3.29 ] CheckMate 066, 2015 1 0% 411 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.96 [0.10 ; 9.32 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 629 low not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.64 [0.05 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.03; 3.20]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.61 [0.14 ; 2.70 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 0% 1,468 low not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
1.00 [0.06 ; 15.97 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.16 [0.02; 1.37]
CheckMate 238, 2017 0.10 [0.01; 1.82]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.40 [0.12 ; 1.35 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.50 [0.02; 14.88]
CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.25 [0.01; 5.54]
CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.36 [0.09 ; 1.38 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6 0% 2,784 low serious Rash TRAE (grade 3-4)detailed results CheckMate 066, 2015 2.00 [0.07; 59.80]
CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.10 [0.01; 0.76]
CheckMate 238, 2017 0.35 [0.13; 0.98]
0.29 [0.13 ; 0.66 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), CheckMate 238, 2017 4 0% 2,566 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.12 [0.01; 2.36]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.36 [0.05 ; 2.74 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Sarcoidosis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.18 [0.07; 0.46]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.32 [0.03; 3.13]
0.22 [0.09 ; 0.52 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Stomatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 066, 2015 0.05 [0.00; 0.82]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.20 [0.03 ; 1.34 ] CheckMate 066, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 629 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.79 [0.12 ; 5.19 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 0% 1,468 low not evaluable Uveitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.02; 50.40]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2.00 [0.07; 59.93]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
1.36 [0.26 ; 7.07 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 1,879 low serious Vomiting TRAE (grade 3-4)detailed results CheckMate 066, 2015 1.00 [0.06; 16.02]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.14 [0.02; 1.15]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.48 [0.13 ; 1.71 ] CheckMate 066, 2015, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 5 0% 1,879 low not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.78 [0.12 ; 5.19 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV), IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4 0% 1,468 low not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 18:34 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 360,719,721,720
